Project Grant RM1DA064500
- This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $187,023 to Baystate Medical Center, Inc. in Massachusetts. The purpose is to conduct a mixed-methods study to determine the impact of the state's Behavioral Health Supports for Justice-Involved Individuals (BH-JI) program on healthcare utilization, costs, and overdose outcomes for individuals with opioid use disorder (OUD) upon release from...
- This $147,486 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will support a mixed-methods study examining the predictors and outcomes of methadone and buprenorphine receipt during incarceration. The study will analyze a longitudinal database on health service use and outcomes among 4,558 incarcerated individuals who received these medications from 2016-2023 at a unified jail and prison system in the Northeast....
- The National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, awarded a $1,548,605 Project Grant to the University of Massachusetts Medical School (UMMS) to test the effectiveness of the Jail ECHO Operations, Planning, and Strategy (J-ECHO OPS) implementation strategy to increase access to Medication for Opioid Use Disorder (MOUD) in rural jails. The study, titled "Improving Jail Response to the Overdose Crisis: A Hybrid Trial of Jail...
- The National Institute on Drug Abuse (NIDA) has awarded a $731,275 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Massachusetts Medical School (UMMS) to support the "Supporting Treatment Access and Recovery in Re-entry (STAR-R)" study. The 5-year study will evaluate the effectiveness of the "Maintaining Independence and Sobriety through Systems Integration, Outreach, and Networking-Criminal Justice Version (MISSION-CJ)"...
- This Project Grant award of $722,917 from the National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services, will fund a 5-year study to evaluate a new approach for dispensing methadone to incarcerated individuals with opioid use disorder (OUD) in three state prison systems. The project aims to support widespread implementation of the hospital/clinic designation, which allows carceral facilities to stock and dispense methadone for OUD treatment, by launching a...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a 5-year, $187,164 research project at Temple University to study the impact of Medicaid "Institutions for Mental Diseases" (IMD) waivers on the utilization of medications for opioid use disorder (MOUD) treatment. The key objectives are to: 1) characterize IMD waiver features across jurisdictions to enable comparison, 2) measure the...
- This Project Grant award of $2,332,500.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to transform systems of care in Washington state prisons to better address HIV, HIV risk, and substance use disorders. The key products and services to be delivered include: Building the foundation for a "prison learning health system" to improve the quality, efficiency, and reach of HIV treatment, HIV prevention, and...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a study to optimize opioid use disorder (OUD) treatment in prisons. The key products and services to be delivered include: Validating a 2-item OUD screening tool and an 11-item diagnostic DSM-5 OUD symptom checklist adapted for use in prisons. This will involve validating these tools against...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a study to characterize treatment utilization and identify predictors of treatment engagement during the critical community re-entry period for adults with opioid use disorder (OUD) who have completed residential OUD treatment. The $147,486 award, with a performance period from December 20, 2024 to August 31, 2026, will leverage innovative...
- This $825,383 federal Project Grant award was provided by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), to the University of Massachusetts Medical School (UMMS) located in Worcester, MA. The grant supports research to investigate the relationship between disruptions in molecular rhythms in specific cell types of the striatum and opioid use disorder (OUD) using human postmortem brain samples and mouse models. The project aims to...
This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a clinical research hub to study the implementation and impact of a Medicaid Inmate Exclusion Policy (MIEP) waiver in 4 Massachusetts county jails. The $1,600,955 award, effective from Sep 1, 2025 to May 31, 2030, will be administered by the University of Massachusetts. The research aims to understand how the MIEP waiver, which allows Medicaid coverage to be restarted 90 days prior to an inmate's release, impacts service delivery, outcomes, and costs of care for individuals with opioid use disorder transitioning from incarceration to the community. The project will leverage existing partnerships and innovative data linkages to examine service utilization, medication-assisted treatment initiation and retention, and overdose outcomes before and after jail release.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 8/27/25 |